IONIS-FB-LRx for Age-Related Macular Degeneration
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called IONIS-FB-LRx to see if it can slow down eye damage in people with a specific type of age-related vision loss. The study focuses on patients whose condition typically worsens over time and aims to find better treatment options by reducing harmful activities in the eye.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude those on chronic steroid treatment. It's best to discuss your specific medications with the trial team.
Eligibility Criteria
This trial is for adults with Geographic Atrophy due to Age-Related Macular Degeneration. Participants must have a certain level of vision, be non-pregnant, non-lactating, and not recently treated with steroids or other investigational drugs. They should also be vaccinated against specific infections.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive IONIS-FB-LRx or placebo subcutaneously every 4 weeks, completing the treatment period at Week 45
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- IONIS-FB-LRx
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ionis Pharmaceuticals, Inc.
Lead Sponsor
Dr. Brett P. Monia
Ionis Pharmaceuticals, Inc.
Chief Executive Officer since 2020
PhD in Pharmacology from the University of Pennsylvania, BSc in Molecular Biology and Analytical Chemistry from Stockton State College
Dr. Eric Bastings
Ionis Pharmaceuticals, Inc.
Chief Medical Officer
MD